OBJECTIVE: To investigate the relationships between the A±G point mutation at position 73826 bp in the 5
Introduction
Obesity affects up to one third of the American and Canadian adult populations. 1, 2 It has been associated with several metabolic and cardiovascular disorders, and some forms of cancer. 3 The mechanisms leading to an overweight or an obese status appear to be heterogeneous. Genetic factors involved in the modulation of energy intake and the determination of energy expenditure have been receiving increasing attention. It is thought that the genetic component of obesity is dependent upon a large number of genes. 4, 5 Candidate genes potentially associated with the development andaor maintenance of obesity are numerous and include the uncoupling protein 1 (UCP1) gene. This mitochondrial protein is uniquely present in brown adipose tissue (BAT) 6 (for review see Ref. 7) where it serves as a membranous proton transporter. UCP1 dissipates the proton electrochemical gradient generated in the mitochondria by short-circuiting the ADP phosphorylation system, resulting in energy dissipation as heat. 8, 9 It has been suggested that the UCP1 system in BAT could act as an important site of facultative energy expenditure and provide a defence against obesity. In a study of 261 subjects from 64 families of the Quebec Family Study (QFS), 10 a Bcl 1 restriction fragment polymorphism of the UCP1 gene was identi®ed using a human genomic probe. Two alleles of 8.3 kb and 4.5 kb with frequencies of 0.28 and 0.72, respectively, were described. A higher frequency of the 8.3 kb allele was found in high gainers compared to low gainers (that is above and below the median value) for percent body fat over a 12 y period. This study showed that DNA sequence variation in the UCP1 gene was associated with the proneness to increase body fat content over time. 10 This polymorphic Bcl 1 site in the human UCP1 gene was shown to be a point mutation localized at position 73826 in the 5
H¯a nking domain of the gene (UCP1 A-3826G) which made it possible to genotype this polymorphic site by polymerase chain reaction± restriction fragment length polymorphism (PCR-RFLP).
11
The same UCP1 gene variant has been shown to be associated with high weight gain in morbidly obese Caucasian subjects. 12 In addition, in obese patients submitted to a low calorie diet, the same polymorphism was associated with lower body weight loss. 13 All these results supported the hypothesis of a role of UCP1 and BAT in the body weight regulation of humans. Based on these considerations, we investigated the relationships between the UCP1 A-3826G mutation and obesity related phenotypes in 674 subjects of the Swedish Obese Subjects (SOS) cohorts, and 311 Swedish control subjects.
Material and methods
The SOS study SOS is an on-going nationwide intervention trial designed to determine whether the mortality and morbidity rates among obese individuals who lose weight by surgical means (gastric banding, vertical banded gastroplasty and gastric by-pass) differ from rates associated with conventional treatment. The study design, multicenter recruitment and assessment procedure have previously been reported in detail. 14, 15 In brief, the SOS study consists of three cohorts, a registry of obese subjects, an intervention study in a subset of these individuals and a normal reference population. In this report, subjects from the obese registry and from the normal reference population have been used. Before receiving a health examination, all subjects completed extensive questionnaires on current and past health status, utilization of medical care and medications, socio-economic status, psychological pro®les, dietary habits, physical activity and various aspects of weight history, including age at onset of weight problems, maximal weight ever achieved, recalled weights at ages 20, 30, 40, 45, 50, 55, and recent weight changes in the previous 6, 12 and 24 months. Data presented in this paper are based on a total sample of 985 subjects, aged 38 ± 60 y, including 310 obese males, 364 obese females and 311 age-matched non-obese controls of both genders (54 male and 257 female) from the general Swedish population with a body mass index (BMI)`27 kgam 2 . Using a BMI of`27 as the cutoff, about 10% of the reference population was excluded. A description of the characteristics of the samples is given in Table 1 . We extracted DNA from total blood for all these subjects.
Obesity-related phenotypes
Body weight was measured to the nearest 0.1 kg using calibrated balances or electronic scales. Body height was measured to the nearest 1 cm. The waist circumference was measured midway between the caudal point of the costal arch as palpated laterally and the iliac crest. The hip circumference was measured at the symphysis-trochanter femoris level to calculate the waist-to-hip ratio (WHR). Both girths were recorded to the nearest 1 cm. The BMI was calculated as body weight divided by the square of height (kgam 2 ).
Genetic analyses
Genomic DNA was isolated from whole blood samples by proteinase K and the phenolachloroform extraction procedure followed by dialysis against TE buffer. We used speci®c primers de®ned to cover the UCP1 Bcl 1 restriction site. 11 Each 30 ml of reaction contained 100 ng of genomic DNA, 9 mM of each primer, 1.5 mM MgCl2, 50 mM KCl, 10 mM TrisaHCl pH 8.3, 0.001% gelatin, 200 mM dNTPs and 0.8 unit of Taq polymerase. The reactions were incubated at 94 C for 5 min, 55 C for 4 min, followed by 30 cycles at 94 C for 1 min and 55 C for 1 min, using a Model 9600 Perkin Elmer thermal cycler (Perkin Elmer Cetus Corporation, Mississauga, ON, Canada). PCR reactions were directly digested by adding 5 units of Bcl 1 enzyme (Gebco BRL, Canadian Life Technologies Inc, Burlington, ON, Canada) for 18 h at 50 C and the fragments obtained were separated at 8% acrylamide gel and visualized under UV light after staining with ethidium bromide.
Bcl 1 polymorphism of the UCP1 gene
Using PCR-RFLP, DNA was ®rst ampli®ed to produce a 470 bp fragment overlapping the UCP1 Bcl 1 restriction site. The presence or absence of the restriction site was then veri®ed by digesting the 470 bp fragment with Bcl 1. The less frequent mutated allele generated a 470 bp fragment (A A G mutation), the BMI body mass index.
UCP1 polymorphism and obesity phenotypes in SOS cohorts J Gagnon et al most frequent allele A included the restriction site Bcl 1 generating two fragments, one of 182 bp and one of 288 bp (no A A G mutation). The three possible genotypes were found: UCP1 A-3826G homozygote (GG), UCP1 A-3826G heterozygote (AG), no A A G point mutation homozygous (AA). A summary of the genotypic and allelic frequencies is given in Table 2 . Genotype frequencies were in Hardy-Weinberg equilibrium (Table 2) .
Statistical analyses
The analyses were performed with the SAS statistical software package version 6.11 (SAS, Cary, NC).
Comparisons of the genotype and allelic frequencies among obese and non-obese subjects were performed using chi-square tests. Initially, the three genotypes were compared for the BMI, waist circumference, WHR and weight changes over time phenotypes following the adjustment procedures speci®ed below. Since no differences were found between genotypes, the analyses were extended to the comparisons of carriers vs non-carriers of the mutation. In this case, homozygotes GG and heterozygotes GA were pooled together as carriers of the UCP1 A-3826G mutation and they were compared to homozygotes AA (non-carriers of the A A G mutation). Only the latter results are reported in this paper to facilitate comparisons with previously published studies.
In the obese cohort, body weight, BMI, waist circumference and WHR were adjusted for age, separately for males and females, using regression procedures. Differences in current weight or maximal weight vs weight at the age of 20 y were adjusted for the current age and the length of the follow-up period. A Student t-test was used to test for differences between the carriers and non-carriers of the A A G point mutation in the residual scores derived from the regressions. Age and weight history variables between carriers and non-carriers of the UCP1 A-3826G mutation were also compared using t-tests.
Comparisons were also undertaken between the low and high weight gainers (®rst and last quintiles).
Values are expressed as mean AE standard deviation (s.d.) and statistical signi®cance was set at P 0.05.
Results
Analyses were performed separately in males and females (Table 3) . In both genders, current weight, current age, BMI, waist circumference and WHR were similar in carriers and non-carriers. In addition, no difference was observed in amount of weight gain over time, neither with maximal weight ever achieved minus weight at 20 y, nor with current weight minus weight at 20 y, with or without adjustment for differences in age and time elapsed. Moreover, in both genders, there was no difference between carriers and To further investigate the issue of differences between high and low weight gainers, we divided the subjects into quintiles on the variable current weight minus weight at the age of 20 y. No signi®cant difference was observed in the proportion of carriers and noncarriers by quintile of weight gain (results not shown).
Discussion
The present study addressed the issue of the A A G point mutation (73826) in the UCP1 gene and its association with several obesity related phenotypes in the SOS cohorts. Lowell et al 16 used a transgenic toxigene to create a transgenic mice with primary de®ciency of BAT (UCP-DTA-diphteria toxin A chain transgenic mice) which became overweight three weeks after birth despite eating similar amounts of food as control mice. Recently, Enerba Èch et al 17 studied a UCP-de®cient mice (obtained by targeted inactivation of the gene encoding UCP1) and found that UCP-de®cient mice consume less oxygen after treatment with a b3-adrenergic receptor agonist and were more sensitive to cold than UCP-DTA mice. Surprisingly, this de®ciency caused neither hyperphagia nor obesity in mice fed on either a standard or a high-fat diet. Compensatory mechanisms involving other UCP homologues have been proposed. 
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Another recent study has shown that hyperphagia and obesity are absent when UCP-DTA mice are reared at thermoneutrality (35 C) indicating that, in this model, a de®cit in BAT thermogenesis was involved. 18 Finally, mice de®cient in noradrenaline due to inactivation of dopamine b-hydroxylase, fail to induce UCP expression and are cold-sensitive but not obese. 19 Although reduced thermogenesis did not cause obesity, genetic alterations that increased the levels of UCP (transgenic mice in which the UCP1 gene was driven by the fat aP2 promoter to achieve enhanced expression in fat tissues), thus enhancing thermogenesis, prevented obesity. 20 Such studies provide evidence for a causal relationship between brown fat thermogenesis and obesity in rodents. Despite the fact that BAT dysfunction is a well established phenomenon in several animal models of obesity, 21 a controversy persists concerning the physiological signi®cance of BAT in humans. Its role in the development or maintenance of human obesity is still a matter of debate.
22
High levels of UCP1 were measured by immunodetection in perirenal adipocytes of adult humans with pheochromocytoma, 23, 24 a condition known to increase brown fat perirenal depot. UCP mRNA was also detected in such patients. 25 In adults without pheochromocytoma, low concentrations of UCP1 were found by solid-phase radioimmunoassay in axillary and perirenal adipose tissue compared to infants and children. 26 Recently, the presence of UCP mRNA was also demonstrated in adults without catecholamine hypersecretion in perirenal, 27, 28 omental and subcutaneous fat, 28 indicating a widespread representation of BAT in the body. It has been hypothesized that BAT might be responsible for 1±2% of the energy expenditure in humans. A depressed metabolic rate of this magnitude, if not compensated, could promote a weight gain of about 1±2 kg per year. 29 However, so far there is no evidence of a direct relationship between BAT and energy balance or body weight regulation in adult humans. 30, 31 In a study of 261 subjects from the QFS cohort, a Bcl 1 RFLP in the UCP1 gene was shown to be associated with the proneness to gain body fat over 12 y of follow-up. 10 An additive effect of this UCP 1 variant and of the Trp64Arg mutation of the ADRB3 (b3-adrenergic receptor) on weight gain was reported in morbidly obese people. 12 In contrast, we found no effect of the ADRB3 mutation on the SOS cohorts. 32 In the present study, we could not replicate the trend previously found with the UCP1 variant in the French cohort of morbidly obese patients 12 and in the QFS family. 10 The previous studies on this UCP1 variant 10 ±13,33 and the present report, are all ®nding allelic frequencies for the UCP1 A-3826G ranging from about 0.24 ± 0.28 with no signi®cant difference between obese subjects and non-obese subjects. These studies therefore suggest that this UCP1 gene polymorphism is not a major determinant of obesity. It is important to point out that these results do not exclude associations with other UCP1 polymorphisms, since only the Bcl 1 polymorphism has been uncovered and tested so far.
Much attention is now focused on other UCP family members particularly UCP2 and UCP3. While UCP1 is expressed exclusively in BAT, UCP2 is expressed widely 34 and UCP3 is preferentially expressed in skeletal muscle and BAT in humans. 35 Because UCP2 and UCP3 could play a role in energy balance, they become new candidate genes for obesity as they may be associated with compensatory mechanisms potentially involved in the regulation of resting metabolic rate in humans. 36 
Conclusion
The A-3826G mutation in the human UCP1 gene is not associated with any of the obesity-related phenotypes or with weight gain over time in the SOS cohorts.
